APLASTIC ANAEMIA | ASH Publishes Guidelines on Diagnosis and Management of Severe and Very Severe Disease
The American Society of Hematology (ASH) has published updated recommendations addressing the diagnosis and management of severe and very severe acquired aplastic anemia, offering clinicians new guidance to support evidence-based treatment decisions.
Aplastic anaemia is a rare disorder characterized by bone marrow failure and reduced production of blood cells, resulting in pancytopenia and increased risks of infection, bleeding, and fatigue. Severe and very severe forms of the disease represent medical emergencies and require prompt diagnosis and treatment to prevent life-threatening complications.
The newly published guidance reflects the latest evidence and expert consensus on how best to diagnose and manage this complex condition. Recommendations cover several aspects of patient care, including diagnostic evaluation, selection of first-line therapy, supportive care, and management of patients who do not respond to initial treatment.
Current treatment strategies generally focus on two main approaches:
• Hematopoietic stem cell transplantation, considered a potentially curative option for eligible patients, particularly younger individuals with matched donors.
• Immunosuppressive therapy, often combining antithymocyte globulin and ciclosporin, with the addition of newer agents such as eltrombopag to improve response rates.
The guidelines also highlight the importance of comprehensive supportive care, including transfusion support, infection prevention, and multidisciplinary management, to improve patient outcomes.
Given the rarity and complexity of aplastic anaemia, expert-driven recommendations such as these are essential to ensure consistent standards of care worldwide. They also help guide clinicians in making individualized treatment decisions based on factors such as age, donor availability, and disease severity.
For the rare anaemias community, including patients, clinicians, researchers, and advocacy organizations, these recommendations for this serious, yet often overlooked disorder, provide valuable insights into current standards of care and highlight ongoing advances in the management of severe aplastic anaemia.
Continued research and international collaboration remain essential to further improve therapeutic strategies and expand treatment options for individuals affected by this rare but potentially life-threatening condition.
Read the ASH2026 Guidelines HERE.
Source: American Society of Hematology
